Bullish
Evolus ( EOLS ) Q2 Revenue Rises 4%
Evolus ( NASDAQ:EOLS ) , a performance beauty company specializing in aesthetic neurotoxins and hyaluronic acid ( HA ) dermal fillers, reported Q2 2025 results on August 5, 2025. The headline news is a material shortfall in both revenue and earnings, with GAAP revenue reached $69.4 million, ...